Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.
Learn more about Sotyktu – Summary of Product Characteristics.
UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the FDA, representing a major milestone in the treatment of adults with moderate to severe plaque psoriasis. Read more about this groundbreaking development.
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States.
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
